Present at the 14th Annual Biotech in Europe Forum

RNS Number : 9199S

Scancell Holdings Plc

30 September 2014

 



30 September 2014

Scancell Holdings Plc

Scancell to Present at the 14^th Annual Biotech in Europe Forum

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that Dr Richard Goodfellow, Joint CEO of Scancell, is scheduled to present at the 14^th Annual Biotech in Europe Forum for Global Partnering and Investment held in Basel, Switzerland on Tuesday 30 September 2014.  

Dr Goodfellow will participate in the Oncology II - Next Generation Immunotherapies panel discussion at 2pm where he will be joined by leading cancer experts to discuss the increasing role of combination and targeted therapies.

In a corporate presentation at 4.30pm, Dr Goodfellow will provide an update on the progress of the SCIB1 clinical programme and the development of both the ImmunoBody® and Moditope® platforms.  

The Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional.  The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives.

For Further Information:

Scancell Holdings Plc  Dr Richard Goodfellow, Joint CEO  Professor Lindy Durrant, Joint CEO		[phone]
FTI Consulting Simon Conway Mo Noonan		[phone]

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

END

 

 

NRASEIFMUFLSEEU